Analysis reveals a novel model predicting clinical outcomes and risk scores in diffuse large B-cell lymphoma, suggesting potential therapies with oxaliplatin and venetoclax.
Key Points
Survival analysis indicated that patients in low-risk groups had improved overall survival compared to high-risk patients due to mitochondrial energy metabolism.
The constructed model’s predictive performance was validated using time-dependent ROC analysis to demonstrate its clinical relevance in DLBCL.
Assessment of immune profiles showed that high-risk patients had lower immune scores, suggesting altered tumor immune microenvironment dynamics.
High-risk patients may benefit from targeted therapies, with risk scores correlating strongly with the expression of key immune checkpoint genes.